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Abstract
Background: Protein Disulfide Isomerase (PDI) in the endoplasmic reticulum of all cells catalyzes the rearrangement of
disulfide bridges during folding of membrane and secreted proteins. As PDI is also known to bind various molecules
including hormones such as estradiol and thyroxin, we considered the hypothesis that adverse effects of endocrine-
disrupter compounds (EDC) could be mediated through their interaction with PDI leading to defects in membrane or
secreted proteins.
Methodology/Principal Findings: Taking advantage of the recent description of the fluorescence self quenched substrate
di-eosin-oxidized-glutathion (DiE-GSSG), we determined kinetically the effects of various potential pharmaceutical EDCs on
the in-vitro reductase activity of bovine liver PDI by measuring the fluorescence of the reaction product (E-GSH). Our data
show that estrogens (ethynylestradiol and bisphenol-A) as well as indomethacin exert an inhibition whereas
medroxyprogesteroneacetate and nortestosterone exert a potentiation of bovine PDI reductase activity.
Conclusions: The present data indicate that the tested EDCs could not only affect endocrine target cells through nuclear
receptors as previously shown, but could also affect these and all other cells by positively or negatively affecting PDI activity.
The substrate DiE-GSSG has been demonstrated to be a convenient substrate to measure PDI reductase activity in the
presence of various potential EDCs. It will certainely be usefull for the screening of potential effect of all kinds of chemicals
on PDI reductase activity.
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Introduction
Endocrine-disrupting compounds are commonly considered as
molecules acting either by mimicking or by blocking the
transcriptionnal activation of hormone nuclear receptors such as
those for estrogens, androgens, progestagens, thyroid hormones
etc [1,2]. Nevertheless, other pathways are now taken into
consideration because these hormones can affect nuclear receptors
indirectly [3] or act through non-genomic pathways [4] or can
bind to non-receptor cellular proteins [5].
In the frame of the european Food & Fecundity project (http://
foodandfecundity.factlink.net/180095.1/), one of the main strategic
objectives was to identify pharmaceutical products as potential
endocrine disruptors of reproductive function and to determine their
adverseeffectsandmechanismsofactioninin-vitro and in-vivosystems.
A prioritization list of seven pharmaceutical products bearing a
potential of affecting human fecundity by entering the food chain has
been created on the basis of production volume, recognized presence
in environment and documented effect(s) on reproduction [6]. The
main drug of concern in this respect was 17a-ethinylestradiol that is
the estrogenic component of most contraceptive pills.
Besides, it has been reported that Protein Disulfide Isomerase
which catalyzes oxidative folding of proteins [7] in the endoplas-
mic reticulum has also been found to be a high-capacity binding
protein for 17b-estradiol [5]. It was also found by the same authors
that 17b-estradiol displayed an inhibitory effect on isomerase
activity of PDI using scrambled RNA as substrate [5]. Taking this
information into account, we considered the hypothesis that EDCs
could exert part of their effects by affecting PDI properties. We
have thus undertaken a study of the influence of estrogens as well
as other pharmaceuticals of interest on another enzymatic function
of PDI, i.e. its disulfide reductase activity.
Results
Preliminary control experiments were carried out in order to
check whether reduction of DiE-GSSG by another enzyme than
PDI or its cleavage by various proteases or conformational
changes could interfere in the assay (see figure S1 in supplemen-
tary data). We found that on a molar basis, thioredoxin exhibited
less than 0.1% reductase activity on DiE-GSSG compared to PDI.
Likewise, Glutathion Reductase either in the presence of 1 mM
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Several proteolytic enzymes (trypsin, thrombin, collagenase-
dispase, leucine-aminopeptidase and carboxypeptidase) were
tested and found to be without any effect on DiE-GSSG
fluorescence. Moreover, neither 0.1% Tween nor 0.5 M concen-
trations of sodium chloride or ammonium sulfate had any direct
effect on DiE-GSSG fluorescence. All these negative controls
indicate that the reductase assay using DiE-GSSG as a substrate is
highly specific for PDI (see supplementary material).
Figure 1A shows the kinetics of DiE-GSSG reduction catalyzed
by bovine liver PDI. A dose-dependent inhibition of PDI by EE2
can be evidenced through the measurement of the initial rate of
the reaction. Figure 1B shows that the kinetics of DiEGSSG
reduction by PDI as followed by EGSH fluorescence is insensitive
to the presence of ethanol up to 10% (v/v). In figure 1A, the
maximum ethanol concentration (for EE2 1 mM) is less than
0.01%. The estrogens E2 and DES exhibited similar effects as EE2
as shown in figure 2. Indeed, figure 2 reports the effects of
increasing concentrations of the various estrogenic EDCs under
study (E2, EE2, DES) on the initial velocity of PDI activity using
DiE-GSSG and DTeT as co-substrates. Interestingly, the three
estrogenic molecules exhibit a significant inhibitory effect on PDI
activity starting at concentrations as low as 10
28 M. BPA was also
found to exert a partial (20%) inhibitory effect on PDI reductase
activity but only at concentrations higher than10
24 M (not
shown).
Figure 3 shows the effects of three non-estrogenic potential
EDCs, MPA, 19-NT and IMT, on PDI activity. Only IMT
exhibits an inhibitory effect which is however much less important
than that of estrogenic molecules (fig. 2). By contrast, the two non-
estrogenic steroids MPA and 19-NT exhibit a potentiation effect
on PDI reductase activity but only above 10
25 M for 19NT.
In addition we checked that 10
24 M bacitracin that is a known
inhibitor of PDI activity [8,9] also exhibited such an inhibitory
activity in this protocol (not shown).
Figure 1. PDI-catalyzed reduction of di-eosin oxidized-glutathion (DiE-GSSG) in the absence or presence of increasing
concentrations of ethynylestradiol (EE2). A/ Kinetics of PDI-catalyzed reduction of DiE-GSSG in the absence or presence of increasing
concentrations of ethynylestradiol (EE2). PDI activity is determined using initial velocity of the reaction as measured through the abolishment of
fluorescence self quenching in 2.4 mM DiE-GSSG when it is reduced into two molecules of E-GSH in the presence of 33 mM DTeT. B/ Comparison of
Kinetics of PDI-catalyzed reduction of DiE-GSSG as in A/ in the absence (#) or presence (N) of 10% (v/v) ethanol in the 100 mM phosphate buffer
pH 8.0.
doi:10.1371/journal.pone.0009507.g001
Figure 2. Dose-dependent inhibition of PDI reductase activity
by the estrogenic compounds E2 (#), DES (N) and EE2 (%). PDI
activities represent initial velocities determined by kinetics of DiE-GSSG
reduction as described in fig. 1.
doi:10.1371/journal.pone.0009507.g002
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Protein Disulfide Isomerase (PDI) is a multifunctional enzyme
mainly found in the endoplasmic reticulum of eukaryotes where its
main function is to catalyze the rearrangement (isomerization) of
disulfide bridges during folding of membrane and secreted
proteins. Its concentration in the lumen of the endoplasmic
reticulum is known to be very high [10] and it has been reported to
act as a high capacity reservoir for various ligands including
hormones such as estradiol (E2) and thyroxine (T3) [5,11]. This
ability of PDI to bind a large number of different molecules
prompted us to search whether potential encocrine disruptor
compounds (EDCs) could exert an influence on its reductase
activity. For this matter, we used the recently described
fluorescence self-quenched substrate DiE-GSSG [12] that is easier
to synthesize and exhibits a much higher signal than the previously
described substrate di-aminobenzoyl-GSSG [13].
Since eosin fluorescence in DiE-GSSG is quenched because of
the vicinity of eosin-goups at the N-termini of oxidized glutathion
(GSSG), it was important to check that reduction by another
enzyme than PDI or proteolysis or conformational change of
GSSG could not interfere in the assay. Thioredoxin exerted a very
marginal DiE-GSSG reducing activity (0.1%) compared to PDI.
This observation indicates that the b and b’ domains of PDI [14]
play an important role in addition to the thioredoxin-like a and a’
domains to permit efficient reducing activity on DiE-GSSG.
Glutathion Reductase was found to be devoid of activity whatever
reducing co-substrate was used (1 mM NADPH or 33 mM DteT).
None of the tested or proteases provoked any change in DiE-
GSSG fluorescence. All these data indicate that DiE-GSSG is a
highly specific substrate for the measurement of PDI reductase
activity.
The most interesting observation was that the three estrogenic
molecules that have been tested (E2, EE2 and DES) exerted an
inhibitory effect on PDI reductase activity. This inhibition was
observed with concentrations as low as 1–10 nM. These very low
concentrations were unexpected as a Kd of 2.1 mM had been
previously determined for the binding of E2 to rat PDI [5]. A
possible origin of the observed discrepancy is that these authors
studied recombinant rat PDI expressed in E. coli [[15,16]]
whereas bovine liver PDI was used in the present study. It can be
suspected that the redox potential in endoplamic reticulum
environment, less reductive than that in bacteria, is of utmost
importance for the correct folding of PDI and consequently
recombinant PDI expressed in E.coli might be unappropriate.
An inhibitory effect of micromolar concentrations of E2 on the
isomerase activity of the recombinant rat PDI in the RNA
refolding assay had been observed [5]. In the present work, we
followed the reductase activity of bovine liver PDI instead of its
isomerase activity. Therefore, it could also be that estrogens exert
their effects on these two activities of PDIs at different
concentrations. Nevertheless, in both cases estrogens have been
shown to interact with PDI and to inhibit its activities. Numerous
EDC affecting reproduction are estrogenic molecules such as EE2,
DES, BP-A etc… [17–19]. The observation of diminished PDI
reductase activity in the presence of physiological concentrations
of estrogens indicates that these hormones might have an
inhibitory effect on the synthesis and secretion of proteins
including by cells not expressing estrogen receptors. It must also
be taken into consideration that PDI can be found at the surface of
plasma membrane where it is thought to exert various functions
[20]. Circulating estrogens could thus be expected to play a role at
this level.
The data in the present paper also show that non-estrogenic
steroids such as the progestagen MPA and the androgen 19NT not
only do not exhibit any inhibiting effect on PDI reductase activity
but, in contrast, exert unexpected potentiation effects.
Previous papers have reported interaction of PDI with
estrogenic molecules such as estradiol [5,21–23] or bisphenol-A
[24,25]. It has also been shown to interact with other hormones
such as T3 [11] and many other molecules. In the present report,
we have focused on the in vitro effects of potential endocrine
disrupters of reproduction on the reductase activity of PDI.
Endocrine disruptor compounds (EDC) are suspected to affect
human and animal health with possible consequences for
development and evolution. Indeed, they act either through
hormone receptors, particularly nuclear receptors [26] or
epigenetically through various mechanisms [4]. Considering the
large amount of PDI in all cells as well as its crucial role in the
correct folding of membrane and secreted proteins in the
endoplasmic reticulum, it is of concern that all the EDCs tested
in present work exhibited negative (estrogens, indomethacin) or
positive (progestagen, androgen) effects on its reductase activity.
These data strongly suggest that EDCs could affect not only
endocrine target cells through nuclear receptors but also all cells
through PDI and consequently by affecting folding of proteins in
the endoplasmic reticulum. Defective protein folding has been
described as a basis for human disease [4,27–29] and should thus
be taken into consideration in the study of detrimental effects of
EDCs.
Extrapolation of the present data to in vivo exposures is obviously
difficult. Obviously, each individual potential EDC tested in the
present study is not expected to reach a sufficient concentration in
vivo to exert by itself a significant effect on PDI activity.
Nevertheless, owing to the large number of molecules able to
interact with PDI, additive or even synergistic effects can be
envisionned and could lead to significant in vivo effects.
The availability of the new substrate PDI DiE-GSSG [12] offers
a rapid and easy way to test all suspected molecules for their
Figure 3. Dose-dependent effect of MPA (#), 19-NT (m) and
IMT(e) on PDI reductase activity. PDI activities represent initial
velocities determined by kinetics of DiE-GSSG reduction as described in
fig. 1.
doi:10.1371/journal.pone.0009507.g003
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Glutathion Reductase reduce DiE-GSSG in the presence of
NADPH or DTeT, this substrate appears to be highly specific for
PDI. This assay should thus be used as a screen to detect molecules
that, individually or synergisticallly, would be potentially harmful
for cell function by affecting protein folding.
Materials and Methods
17b-estradiol (E2), 17a-ethinylestradiol (EE2), diethylstilbestrol
(DES), medroxyprogesterone acetate (MPA), 19-nor-testosterone
(19NT), bacitracin, indomethacin (IMT), bisphenol A (BPA),
dithioerythreitol (DTeT), eosin 5-isothiocyanate, oxidized glu-
tathion (GSSG), Protein Disulfide Isomerase (E.C. 5.3.4.1) from
bovine liver (PDI), Thioredoxin (E.C 1.6.4.5) from spirulina and
Glutahtion Reductase (E.C 1.6.4.2) from S. cerevisiae as well as
the proteolytic enzymes trypsin, thrombin, collagenase-dispase,
leucine-aminopeptidase and carboxypeptidase were all purchased
from Sigma-Aldrich (Isle-d’Abeau, France) and were of the highest
available grades. All steroids were initially disolved in ethanol and
serially diluted in the 100 mM phosphate buffer pH 8.0 used for
the kinetics.
The PDI substrate, di-eosin-oxidized glutathion (diE-GSSG),
was synthesized and purified as previously described [12] with
minor modifications. After final purification on sephadex G50
(Pharmacia, Uppsala, Sweden) in water, aliquots of eluted DiE-
GSSG were freeze-dried and kept in the dark until use.
PDI reductase activity was measured through abolishment of
fluorescent self quenching when DiE-GSSG is reduced into two
molecules of E-GSH. Initial velocities in fluorescence increase
(lexc=518 nm; lem=545 nm) were recorded using a Spectra-
Max Gemini spectrofluorimeter (Molecular Devices, Sunnyvale,
CAL USA) and analyzed with SoftMaxPro program. Concentra-
tions of the reagents at t0 were 200–333 nM for PDI, 2.4 mM for
DiE-GSSG, 33 mM for DTeT and 0.1 nM to 100 mM for the
various molecules under study (E2, EE2, DES, MPA, 19NT and
IMT).
Supporting Information
File S1 Control experiments showing the effects of reductive
enzymes and proteolytic enzymes on DiE-GSSG fluorescence
(lexc=518 nm; lem=545 nm)
Found at: doi:10.1371/journal.pone.0009507.s001 (0.19 MB
DOC)
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